RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares.
Renovorx Inc. (RNXT)
Market is closed
News
- Displaying 2
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 Financial and Operational Highlights Conference Call. All participants will be in a listen-only mode.
Billionaire Hedge Funds
